The Lancet Respiratory Medicine, published by Elsevier in the United Kingdom, is a premier journal dedicated to the field of pulmonary and respiratory medicine. With its impressive impact factor and a prestigious ranking of #1 out of 155 in its category as of 2023, it holds a remarkable position in advancing research and clinical practices in respiratory health. The journal invites original research, reviews, and clinical studies that aim to propel the understanding of respiratory diseases, fostering innovations in treatment and management strategies. Operating under a Q1 category in Scopus rankings, it is an essential platform for researchers, healthcare professionals, and students who are committed to enhancing patient care and advancing knowledge in this crucial area of medicine. The Lancet Respiratory Medicine remains a vital resource for the latest findings and discussions shaping the future of respiratory health.

Therapeutic Advances in Respiratory Disease is a prestigious open-access journal published by SAGE Publications Ltd, based in the United Kingdom. Since its inception in 2007, it has established itself as a leading platform for the dissemination of cutting-edge research in the fields of pulmonary and respiratory medicine and pharmacology. With an impressive impact factor and ranking—showing it is in the Q1 quartile in both Pharmacology (medical) and Pulmonary and Respiratory Medicine as of 2023—the journal's commitment to high-quality research is evident. In 2023, it ranks #32 out of 155 in Pulmonary and Respiratory Medicine and #57 out of 272 in Medical Pharmacology, positioning it in the 79th percentile across these disciplines. Open access since 2018, the journal ensures that its valuable content is readily accessible to a global audience of researchers, healthcare professionals, and students, facilitating the rapid exchange of knowledge that is crucial in the ever-evolving landscape of respiratory health. The journal's objectives include advancing understanding of respiratory diseases through innovative research and promoting the development of therapeutic strategies that improve patient outcomes, making it an essential resource for those dedicated to respiratory medicine.

Minerva Respiratory Medicine is a prominent academic journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by EDIZIONI MINERVA MEDICA in Italy, this journal provides a vital platform for the dissemination of innovative research, clinical studies, and review articles that address the complexities of respiratory health. With an ISSN of 2784-8477 and an E-ISSN of 2724-6493, it serves as an open-access resource, allowing researchers, healthcare professionals, and students access to invaluable information without barriers. The journal is categorized in the fourth quartile of the 2023 rankings in the field of pulmonary and respiratory medicine, indicating its emerging role in the academic landscape. Despite its nascent status—converging from 2021 to 2024—Minerva Respiratory Medicine is committed to enhancing knowledge and practice in respiratory care, focusing on both innovative therapies and traditional approaches. With its aim to foster collaboration and communication among professionals in the field, this journal is an essential resource for those passionate about improving respiratory health outcomes.

Jornal Brasileiro de Pneumologia is a pivotal open-access journal in the field of Pulmonary and Respiratory Medicine, published by SOC BRASILEIRA PNEUMOLOGIA TISIOLOGIA. Established in 2004, this esteemed publication has become a significant platform for researchers, health professionals, and students in Brazil and beyond, facilitating the exchange of innovative ideas and vital research findings. The journal is indexed in Scopus and is recognized in the 2023 category quartiles as Q3, ranking 86 out of 155 in its field with a corresponding 44th percentile. This reflects its growing influence and commitment to advancing knowledge concerning respiratory health. With a mission to disseminate high-quality research, the journal aims to foster advancements in clinical practice and improve outcomes in pulmonary diseases, making it an essential resource for those dedicated to enhancing the quality of care in respiratory medicine. For those seeking comprehensive access to critical studies and reviews in this domain, the Jornal Brasileiro de Pneumologia remains an invaluable asset.

RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY, published by Elsevier, is a prominent journal in the fields of respiratory medicine, neurobiology, and physiology. With an ISSN of 1569-9048 and E-ISSN 1878-1519, this journal serves as an essential platform for disseminating high-quality original research and reviews that explore the intricate relationships between respiratory function and neural controls. Located in the Netherlands, it boasts an impressive standing within its field, categorically placed in the Q3 quartile for Neuroscience and Physiology and Q2 for Pulmonary and Respiratory Medicine according to the 2023 metrics. With a Scopus rank of #58 in Pulmonary and Respiratory Medicine and a robust impact factor indicative of its academic influence, the journal aims to foster advancement in understanding the physiological and neurobiological aspects of respiration. Although the journal is not open access, its content is vital for researchers, professionals, and students eager to contribute to the expanding knowledge base in these critical scientific domains.

Zeitschrift für Pneumologie is a pivotal journal in the field of Pulmonary and Respiratory Medicine, published by Springer Heidelberg, a renowned name in academic publishing. With its ISSN number 2731-7404, it serves as a vital platform for disseminating innovative research and clinical studies relevant to lung health and diseases. This German-based journal aims to bridge the gap between research and practice, encouraging submissions that advance knowledge in respiratory medicine, including pathophysiology, treatment modalities, and patient care strategies. Although currently categorized in the Q4 quartile within its field, its commitment to quality research and emerging insights positions it as an essential resource for researchers, healthcare professionals, and students dedicated to improving respiratory health. The journal operates within the convergence period from 2022 to 2024, promising a dynamic evolution of its content. With limited open access availability, it encourages readership and contribution from its audience, fostering a collaborative academic environment.

Annals of Thoracic Medicine is a prominent open-access journal, published by Wolters Kluwer Medknow Publications, focusing on the critical fields of cardiology, pulmonary and respiratory medicine, and surgery. With an ISSN of 1817-1737 and an E-ISSN of 1998-3557, this journal aims to disseminate cutting-edge research, clinical findings, and innovative practices that can significantly impact the health outcomes of patients dealing with thoracic diseases. Since its inception in 2006, it has established itself as a reputable source of knowledge, achieving Q2 quartile rankings in 2023 across its main categories. Currently ranked #126 in Medicine & Surgery and exhibiting a growing SCOPUS percentile, the journal plays an essential role in advancing the understanding and treatment of thoracic conditions. Open access options ensure that research is readily available to a global audience, facilitating collaboration and knowledge sharing among researchers, healthcare professionals, and students in the field.

Pulmonary Medicine, published by HINDAWI LTD, stands as a prestigious open-access journal since 2010, dedicated to advancing the field of pulmonary and respiratory medicine. Located in Egypt, this journal is indexed with an ISSN of 2090-1836 and an E-ISSN of 2090-1844, and it has attained a commendable Q2 ranking in both the miscellaneous medicine and pulmonary health categories, indicative of its significant impact and quality. With an impressive Scopus ranking of #15 out of 155 in the pulmonary and respiratory medicine category, the journal is positioned in the 90th percentile, highlighting its relevance and contribution to ongoing research. The journal aims to publish high-quality original research, reviews, and clinical studies that address pressing issues in pulmonary health, making it a vital resource for researchers, clinicians, and students seeking to enhance their understanding and practice in respiratory medicine. By embracing an open-access model, Pulmonary Medicine provides a platform for disseminating knowledge, fostering collaboration, and driving innovation within the global scientific community.

REVUE DES MALADIES RESPIRATOIRES is a distinguished journal published by MASSON EDITEUR, focusing on the vital field of pulmonary and respiratory medicine. Established in 1984, this journal has become a prominent platform for sharing innovative research and clinical findings, reflecting an impressive array of studies that contribute to our understanding of respiratory diseases. With its ISSN 0761-8425 and E-ISSN 1776-2588, it facilitates access to scholarly work within the medical community, although it currently operates under a subscription model rather than Open Access. As indicated by its quartile ranking of Q4 in 2023 within its category and a Scopus rank of #128/155, REVUE DES MALADIES RESPIRATOIRES serves as an essential resource for researchers, professionals, and students aiming to stay informed about advancements in respiratory health. This journal plays a crucial role in fostering discussions that drive innovation and best practices in the treatment and understanding of respiratory conditions.

Respiratory Investigation is a leading peer-reviewed journal published by Elsevier, dedicated to advancing the field of Pulmonary and Respiratory Medicine. Since its inception in 2012, the journal has grown to become a vital resource for researchers, clinicians, and students alike, providing a platform for high-quality research articles, reviews, and clinical studies. With a commendable impact factor and ranked in the Q2 category of Scopus' 2023 metrics, it stands at rank #57 out of 155 in its field, illustrating its importance and influence within the academic community. Although the journal operates on a subscription basis, it remains committed to disseminating essential findings that enhance the understanding and treatment of respiratory diseases. Set against the innovative backdrop of the Netherlands, Respiratory Investigation not only serves as a conduit for scholarly exchange but also plays a critical role in shaping future research directions and clinical practices.